Your browser doesn't support javascript.
loading
Improving Hepatocellular Carcinoma Surveillance Outcomes in Patients with Cirrhosis after Hepatitis C Cure: A Modelling Study.
Cumming, Jacob; Scott, Nick; Howell, Jessica; Flores, Joan Ericka; Pavlyshyn, Damian; Hellard, Margaret E; Winata, Leon Shin-Han; Ryan, Marno; Sutherland, Tom; Thompson, Alexander J; Doyle, Joseph S; Sacks-Davis, Rachel.
Afiliação
  • Cumming J; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Scott N; Population Health and Immunity, Walter and Eliza Hall Institute, Parkville, VIC 3052, Australia.
  • Howell J; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Flores JE; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.
  • Pavlyshyn D; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Hellard ME; Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC 3065, Australia.
  • Winata LS; Department of Medicine, University of Melbourne, Melbourne, VIC 3052, Australia.
  • Ryan M; Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC 3065, Australia.
  • Sutherland T; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Thompson AJ; Disease Elimination Program, Burnet Institute, Melbourne, VIC 3004, Australia.
  • Doyle JS; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia.
  • Sacks-Davis R; Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC 3004, Australia.
Cancers (Basel) ; 16(15)2024 Aug 01.
Article em En | MEDLINE | ID: mdl-39123472
ABSTRACT
BACKGROUND &

AIMS:

Hepatocellular carcinoma (HCC) presents a significant global health challenge, particularly among individuals with liver cirrhosis, with hepatitis C (HCV) a major cause. In people with HCV-related cirrhosis, an increased risk of HCC remains after cure. HCC surveillance with six monthly ultrasounds has been shown to improve survival. However, adherence to biannual screening is currently suboptimal. This study aimed to evaluate the effect of increased HCC surveillance uptake and improved ultrasound sensitivity on mortality among people with HCV-related cirrhosis post HCV cure.

METHODS:

This study utilized mathematical modelling to assess HCC progression, surveillance, diagnosis, and treatment among individuals with cirrhosis who had successfully been treated for HCV. The deterministic compartmental model incorporated Barcelona Clinic Liver Cancer (BCLC) stages to simulate disease progression and diagnosis probabilities in 100 people with cirrhosis who had successfully been treated for hepatitis C over 10 years. Four interventions were modelled to assess their potential for improving life expectancy realistic improvements to surveillance adherence, optimistic improvements to surveillance adherence, diagnosis sensitivity enhancements, and improved treatment efficacy

Results:

Realistic adherence improvements resulted in 9.8 (95% CI 7.9, 11.6) life years gained per cohort of 100 over a 10-year intervention period; 17.2 (13.9, 20.3) life years were achieved in optimistic adherence improvements. Diagnosis sensitivity improvements led to a 7.0 (3.6, 13.8) year gain in life years, and treatment improvements improved life years by 9.0 (7.5, 10.3) years.

CONCLUSIONS:

Regular HCC ultrasound surveillance remains crucial to reduce mortality among people with cured hepatitis C and cirrhosis. Our study highlights that even minor enhancements to adherence to ultrasound surveillance can significantly boost life expectancy across populations more effectively than strategies that increase surveillance sensitivity or treatment efficacy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article